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Abstract
Background: It is often stated that external validity is not sufficiently considered in the assessment
of clinical studies. Although tools for its evaluation have been established, there is a lack of
awareness of their significance and application. In this article, a comprehensive checklist is
presented addressing these relevant criteria.
Methods: The checklist was developed by listing the most commonly used assessment criteria for
clinical studies. Additionally, specific lists for individual applications were included. The categories
of biases of internal validity (selection, performance, attrition and detection bias) correspond to
structural, treatment-related and observational differences between the test and control groups.
Analogously, we have extended these categories to address external validity and model validity,
regarding similarity between the study population/conditions and the general population/conditions
related to structure, treatment and observation.
Results: A checklist is presented, in which the evaluation criteria concerning external validity and
model validity are systemised and transformed into a questionnaire format.
Conclusion: The checklist presented in this article can be applied to both planning and evaluating
of clinical studies. We encourage the prospective user to modify the checklists according to the
respective application and research question. The higher expenditure needed for the evaluation of
clinical studies in systematic reviews is justified, particularly in the light of the influential nature of
their conclusions on therapeutic decisions and the creation of clinical guidelines.
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Background
It is known that clinical studies can generate discordant
results. This observation is addressed scientifically in vari-
ous ways. Deviant study results may be understood as an
expression of spreading or scattering from a supposed true
value (whereas deviation depends on the precision of the
methods). An alternative approach is to explain differ-
ences not statistically but by way of content [1]. In consid-
ering individual studies, there should be an estimate to
what extent the study conclusions are distorted by system-
atic factors of bias. Here the focus lies usually on so called
internal validity, the comparability of test and control
groups. (Detailed definitions of internal validity and
other validity categories are given in the methods section).
When assessing internal validity a differentiation is made
between the following factors:
 Selection bias: differences between test and control
population regarding their structural composition, e.g. in
terms of age, gender, duration and severity of illness and
others.
 Performance bias: differences in the treatment  apart
from the intervention tested, e.g. more contact, attention
or efforts in the verum group.
 Detection bias: differences in observation of outcome
parameters, e.g. due to inadequate blinding and respective
expectations by assessors, due to training effects or others.
 Attrition bias: related to differences in dropouts
between test and control group.
The goal is to gain the largest possible level of structural,
treatment-related and observational similarity between
test and control groups through randomisation and blind-
ing, with a subsequent evaluation following the "inten-
tion to treat" (ITT) principle [1-3]. Studies with relative
good avoidance of selection, performance, attrition and
detection bias, in relation to the test and control popula-
tions, are classified as internally valid. Scoring systems
have been developed to support the evaluation of internal
validity (e.g., the Jadad Score) [4-6] and assessment crite-
ria of internal validity are also reflected in the EBM hierar-
chy of study types [7-9]. In contrast, aspects of external
validity that refer to the comparability between the study
population and the general population of interest are
often neglected in quality assessment and are usually not
considered as having a possible distortive effect on an arti-
cle's conclusion [10,11]. Rothwell stated in 2005 [11]:
"There is concern among clinicians that external validity is
often poor [...]. Yet researchers, funding agencies, ethics
committees, the pharmaceutical industry, medical jour-
nals, and governmental regulators alike all neglect exter-
nal validity, leaving clinicians to make judgments.
However, reporting of the determinants of external valid-
ity in trial publications and systematic reviews is usually
inadequate [...]."
Factors that can lower the representativeness of a study
population and thus the external validity are for example:
 Process of consenting: patients who give their consent
to participate have been shown to differ largely in severity
of illness and other parameters to those who do not give
their consent [12,13].
 Consenting and selection criteria: Emmerich et al. [14]
interpret the fact that only 7–8% of possible study partic-
ipants were included in a study in that way that the study
population was highly selected, well motivated with good
levels of compliance and better probable outcomes than
the "real-life" patients. The most frequent exclusion crite-
ria were relative contraindications to the study interven-
tion and refusal of participants.
 Patients' preferences: Protheroe et al. [15] showed that
the discrepancy between clinical guidelines and their prac-
tical application becomes larger when patient preferences
are considered. According to their decision analysis only
60% of patients with atrial fibrillation had preferred anti-
coagulation, which was far less than those who would
have been recommended by guidelines (up to 90%).
When interpreting data on patients' preferences one
should consider that answers in questionnaires or inter-
views are often discordant with actual decisions.
 Furthermore, commonly neglected factors that limit the
validity of study results, according to Rothwell [11], are as
varied as differences in health care systems, national char-
acteristics and regulations, characteristics of the participat-
ing centres and the level of physicians' specialisation (for
example, being limited to "special care units").
Regarding such contextual differences one should also
distinguish, on the one hand, services' ability to
deliver and, on the other hand, clients' uptake and
potential to benefit.
 Other factors include the choice of outcomes: surrogate
parameters, e.g. laboratory values instead of clinical val-
ues, and relevant parameters for the patient (general and
mental health, emotional balance, vitality and quality of
life), all of which are seldom charted in randomised con-
trolled trials (RCTs).
Rothwell suggests that there should be a stronger consid-
eration of external validity criteria in the evaluation of
clinical studies, even in guidelines such as the CONSORT
[16] or Cochrane Collaboration guidelines [2]. This issueBMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
Page 3 of 13
(page number not for citation purposes)
was taken up by Glasgow and colleagues [17] in 2005.
Concrete proposals for assessing generalisability in trials
of health care interventions were made by Bonell et al. in
2006 [18].
The tools required to evaluate external validity are, in
principle, not new – the relevant criteria have been used
in methodology lectures for medical students, and are
found in many guidelines for the evaluation of clinical
studies. It seems, however, that there is a deficit in both
the awareness of the actual necessity for this evaluation
process and in the actual application of the assessment cri-
teria.
With this article, we present a checklist that encompasses
the most important quality assessment criteria regarding
external validity and model validity criteria. These criteria
have been systematised and have been formulated in
operable questions.
Methods
The checklist has been developed by listing the most com-
monly used assessment criteria for clinical studies [2-
4,9,11,16,19-38] and by using specific criteria lists for
individual applications. These include, for example: surgi-
cal interventions [39], so-called practical clinical studies
which are characterised particularly by a larger amount of
heterogeneity of population, intervention and outcome
criteria [40], observational studies [41], single case analy-
ses of oncology patients [28], the aforementioned criteria
regarding external validity published by Rothwell [11],
and model validity published by Wein [37], and our own
assessment criteria: We extrapolated key elements from
internal validity to external validity, adapting them where
necessary. We integrated questions from the above men-
tioned lists into the scheme of external validity and added
criteria derived from the practical experience of the
authors (clinical as well as methodological experts). We
tested the checklist on two occasions when performing
systematic reviews [42,43].
The systemisation of the criteria has been carried out using
the "PICOS" categories (Population, Intervention, Con-
trol, Outcome, Setting), and by using the assessment cate-
gories regarding internal validity, external validity, model
validity, and general study quality. In the following only
the essential aspects of external and model validity are
pursued.
Definitions
 The term "internal validity" (IV) refers to the "confi-
dence that the trial design, conduct, and analysis has min-
imized or avoided biases in its treatment comparison"
[44] and is considered as "a measure of the strength of the
association between exposure or intervention and out-
come within a study" [9]. Internal validity relates to all
comparisons made between the test intervention and the
controls, not only in RCTs.
 The term "external validity" (EV) refers to generalisabil-
ity (i.e. the extent to which the effects observed in a study
truly reflect what can be expected in a target population
beyond the people included in the study [2]), which
includes the possibility to transfer and apply study results
to a distinct population/decision and patient's situation.
The most important criteria are conformity with everyday
practice and clinical relevance. Difficulties in assessing EV
derive from the point that the target population and target
setting – for which the study claims to be valid – is com-
monly not described explicitly. The so-called everyday
practice or everyday efficacy is sometimes hard to define
as well. Moreover this outer context may change with time
(e.g. mutation of infectious agents).
A good external validity in a sense of an adequate
reflection of reality (is it correct?) does not necessarily
mean a good (external) utility in a sense of a useful
reflection of reality (what is it good for? e.g. in terms
of patients' quantity and quality of life)
 The term "model validity" indicates the concordance
between the study design and an ideal setting, e.g. the
"state of the art" procedures (see Wein [37]).
The differentiation between EV and MV is not very wide
spread. The distinction between everyday conditions and
ideal conditions becomes important when switching the
focus from the confirmation of an efficacy in principle to
the question of a broader application of an intervention
("everyday effectiveness"). In the first, it is important to
have ideal conditions such as well trained and highly
experienced therapists, a population which is supposed to
be very sensitive to the intervention, outcome parameters
that reflect the intervention effect the best and a setting
that ensures an optimal compliance (e.g. application of a
medication by intravenous infusion in a hospital instead
of oral application at home). In the second, factors such
as practicability of an intervention (e.g. by GPs), accessi-
bility for patients to an intervention, frequency of con-
comitant diseases and medications, which may be
contraindications to the intervention, patients' and thera-
pists' preferences and others become more important.
It is often assumed that statements or conclusions con-
cerning the efficacy are solely related to IV, and EV can
only be used to generate statements concerning the extent
of validity (or limits of generalisation). However, we take
the position that insufficient MV and also EV can distort
statements concerning the efficacy/effectiveness. For this
reason, the possibilities of bias, in analogy to the IV, haveBMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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been carried over into the categories of EV and MV. The
principle of this extrapolation is shown in table 1, where
the contrasting aspects between internal and external
validity in respect of the above mentioned bias factors is
compiled.
Results
The checklists for assessing external and model validity
are compiled in table 2 and 3.
To answer the questions regarding the EV and the MV, cer-
tain information should be collected (table 4).
Beside the use in a sequential form as seen in table 2 and
3 one can also consider a parallel form (Figure 1).
The complete questionnaires (including those for internal
validity and general study quality) can be obtained by
authors.
Discussion
With this compilation of important parameters for MV
and EV we propose a checklist, which on the one hand can
be used for planning and on the other hand for evaluation
of clinical studies. We would like to stress that adjust-
ments or even more extensive modifications can be neces-
sary according to the concrete questions of interest.
According to our experience in most studies only a few
aspects are crucial for the quality of the validities, while
others are only of marginal importance. Some studies may
lose their significance and relevance due to one single cru-
cial error while other studies will not despite several but
less important parameters judged as insufficient. Estab-
lishing and using scores harbours the risk of pseudo-accu-
racy. Therefore we rather suggest a descriptive evaluation,
where scores should only be used to verify one's own eval-
uation.
The parameters necessary for the evaluation of the EV and
MV should be discussed for each research question and
application individually. The validity of data needed to
determine these criteria is another crucial point. We rec-
ommend to avail oneself of the principles of maximal and
minimal contrasting as they have worked out well in qual-
itative research strategies: to look for perspectives on a
chosen item as different as possible for maximal contrast
(e.g. therapists, methodological experts, patients and rela-
tives in respect to a special disease) and to look for at least
2 representatives of each perspective for minimal contrast-
ing. (General perspectives would be those of bearing
responsibility for a decision/deed, implementing it and
being affected by it). Gathering the data can be done by
questionnaires or structured interviews using the items of
the checklists (table 4). As for the validity of these col-
lected data it appears adequate from a pragmatic point of
view to consider congruent answers as reliable and deduct
the reference data from them, whereas incongruent
answers require further analysis. Published data on epide-
miology or about clinical studies should be included in
the process of compiling reference data. It can be expected
that with more thorough consideration of the criteria for
EV and MV in study designs future data will have higher
validity. As a further result of systematic collected data
according to a checklist gaps of knowledge may become
evident that could possibly be addressed by additional
investigations or studies.
When applying criteria of IV, EV and MV mostly not all of
these criteria will be fulfilled to the same extent. That
means that studies will usually not be "optimal". Which
aspect will be prioritised depends on the question of the
study. In the systematic reviews we performed using the
checklist for EV and MV [41,42] we identified other stud-
ies as being of high quality than using criteria of IV alone.
Most of the studies only considered aspects of IV. In one
review [42] the assessment of effectiveness changed in
favour to the treatment when prioritising aspects of exter-
nal validity.
An explanatory study investigating causal connections
(e.g. efficacy) will focus on IV although EV and MV should
not be neglected, whereas in health-care research the pre-
sented aspects of EV should be of primary importance. To
obtain a high IV or MV the study population should be as
homogeneous as possible, while in evaluating EV it is of
great interest to what extent the intervention is also appli-
cable among a heterogeneous population and under het-
erogeneous conditions, particularly with concomitant
diseases and co-medications. Homogeneity within a
group is usually attained by restrictive inclusion and
exclusion criteria, homogeneity and comparability
between groups by randomisation. With regard to IV it is
the best method since randomisation is the only adequate
means to reduce the risk of the unequal distribution of
unknown confounding factors. EV is, as presented above,
with high probability affected by the randomisation
[11,14,15].
Furthermore, it can be assumed that the MV (which may
be already distorted through the selection process alone)
will be impaired since the ethically and methodically
requested prerequisites for the randomisation – the so-
called equipoise, i.e. the unbiased position of the investi-
gator in respect of intervention and control – may not be
sufficiently fulfilled. Great experience (high MV!) presum-
ably comes along with therapist's preference for a certain
intervention, which may interfere with the required neu-
trality towards the treatment options. To consider the
therapy preferences of the physician and the patient
within a study corresponds to a high MV and EV.BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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Table 1: System of bias factors, which may affect internal and external validity
Bias factors Internal validity External validity/generalisability
Selection bias Problem Treatment and control group are different, e.g. 
differences in age, severity of disease
Study group and "target group" are different, study 
group is not representative, e.g. differences in age, 
severity of disease
Solution Randomisation, matched pairs Identification (and adjustment as far as possible) of 
relevant epidemiological factors, e.g. by comparison 
with patients who have not consented in the study
False negative/positive results may occur: –: relevant distinctions/subgroups unknown → 
levelled outcome
+: e.g. treatment group with more "responders"
+/–: e.g. study group with more advanced disease 
(university hospital)
+: e.g. study group without concomitant diseases 
(better prognosis than "usual" patients)
Key questions Is randomisation adequate?
Are (known) relevant factors distributed equally?
Are relevant epidemiological factors taken into 
account?
Performance bias Problem Apart from the intervention tested, groups are 
treated differently
Study treatment does not reflect the actual 
variability in managing disease and patients' 
problems
Solution Blinding, documentation of possible differences, 
change to open label design (COLA design)
Treatment as realistic as possible with 
individualised modification if necessary (pragmatic 
controlled trials)
False negative/positive results my occur: –: concomitant therapy in control group; non 
compliance in verum group;
+: concomitant therapy in verum group
+: high compliance (e.g. in hospitals); highly 
specialised therapists; high dosages of medication
–: relevant context factors are missing (patient-
therapists relationship, accessibility to therapy); 
inexperienced therapists; low dosages of 
medication
Key questions Is blinding adequate and checked? Are concomitant 
interventions documented?
Are realistic interventions applied which are 
carried out by physicians in everyday practice?
Attrition bias Problem Drop out rates between groups are different or 
that large that analysis is not reliable any more
Drop out rates between study group an target 
group are different, e.g. different compliance and/or 
motivation
Solution Intention to treat analysis (note: drop out rates > 
10 % have a high risk of bias)
Compliance control and assessment
False negative/positive results may occur: – : intention to treat analyses
+: drop out rates are higher in treatment group 
(with per protocol analyses)
–: drop outs due to adverse effects (and intention 
to treat analysis)
+: drop outs due to ineffectiveness of therapy (and 
per protocol analysis)
Key questions Is the drop out rate documented? Are adequate 
analyses performed?
Are the reasons for dropping out documented? Do 
the reasons for dropping out have an impact on the 
assessment of compliance, effectiveness or safety?
Detection bias Problem Differences in the perception of outcome 
parameters between groups and within the the 
course of the study
Outcome parameters and/or length of follow up 
have no practical relevance to patients' problems
Solution Blinding of assessors; if blinding is not possible: 
assessment of two independent persons; objective 
parameters
Selection of clinically relevant and generally 
available outcome parameters; adequate length of 
follow up
False negative/positive results may occur: –/+: inadequate blinding and respective 
expectations by assessors
–: outcome parameters do not reflect actual 
improvement; inadequate follow up
+: significant but irrelevant outcomes
Key questions Blinding procedures of assessors adequate? 
Independent assessors?
Are outcome parameters, length of follow up and 
detected differences relevant?BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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Table 2: Questions for assessing external validity (EV)
Categories Items +( + )-c . b . e .
Study population – assessment of 
selection bias (related to EV)
• To what extent do the inclusion and exclusion criteria (where relevant, other 
selection criteria) define the "everyday or target population" of the intervention?
• Does the applied diagnostic procedure reflect everyday conditions and the everyday 
possibilities (access, necessity) respectively?
• Are the diagnostic procedures and evaluations performed by persons with similar 
qualification and experience as in everyday practice?
• Does the study population reflect the everyday population in terms of:
❍ Severity of the illness
❍ Duration of illness
❍ Intra-individual variability
❍ Age
❍ Gender
❍ Further socio-demographic characteristics
❍ Therapy preferences and expectations
❍ Symptoms of side effects of the interventions
❍ Accompanying illnesses
❍ Accompanying medication
❍ Further prognostic or therapy relevant parameters?
• Has the structural similarity between the study and the everyday population or target 
population been tested?
Intervention und control – 
assessment of performance bias 
(related to EV)
• Does the preparation (medication, other medicinal products, other kind of 
interventions) reflect the usual treatment?
• In case of medication, does the dosage reflect the usual treatment? (Is dose 
modification possible?)
• Does the type of administration reflect the usual treatment?
• Does the intervention duration reflect the usual treatment duration?BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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• Are the permitted accompanying treatments the usual accompanying treatments?
• Does the study situation reflect the common treatment situation?
• Are the interventions carried out by therapists with similar qualifications and 
experience as in everyday practice?
Outcome measurements, results 
and evaluation – assessment of 
detection and attrition bias (related 
to EV)
• Are the chosen outcomes practice and patient relevant? (E.g. no surrogate parameter, 
are individual therapy goals defined?)
• Were the following important outcomes considered: quality of life, subjective health, 
patient's general evaluations, compliance, reasons for dropout, use of accompanying 
treatments, rebound effect following termination of treatment (or, for example, 
symptom deceit)?
• Are the test procedures used in usual practice?
• Are the tests and evaluations performed by persons with similar qualifications and 
experience as in every day practice?
• Are the differences clinically relevant?
• Were sufficient data collected to cover the intra-individual variability?
• Do the test conditions reflect the everyday practice?
• Does the dropout rate reflect everyday experience? Are the reasons for dropout 
registered (e.g. adverse effects, insufficient effect), so that the significance for the 
everyday effectiveness can be assessed?
• Is clinical relevance considered in the conclusion?
Study design and Setting (related to 
EV)
• Is the research question clinically relevant?
• Does the study design ensure a high EV?
• Does the study setting reflect the everyday conditions?
• Are the investigators the regular contact persons (e.g. GP or relevant clinic doctor, or 
are they at least comparable in terms of training, status, experience, preferences; does 
the number of contact people reflect the usual setting)?
• Does the doctor/therapist-patient relationship reflect the everyday conditions (e.g. 
frequency of contact, constant contact person)?
+ Matches completely/is completely fulfilled
(+) Matches incompletely but sufficiently/is only partly but sufficiently fulfilled
- Does not match or matches insufficiently/is insufficiently fulfilled
c.b.e. Can not be evaluated
Table 2: Questions for assessing external validity (EV) (Continued)BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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Table 3: Questions for assessing model validity (MV)
Categories Items + (+) - c.b.e.
Study population – assessment of selection bias (related to MV) • To what extent do the inclusion and exclusion criteria and, where relevant, 
other selection criteria define an optimal population with respect to the test 
intervention? (An optimal population will show the highest benefit from the 
applied intervention).
• Is the applied diagnosis and/or classification relevant for the intervention?
• Are relevant subgroups considered?
• Does the diagnostic procedure optimally reflect the aptitude for the 
intervention?
• Are the diagnostic procedures performed by qualified and experienced 
physicians?
• Does the study population reflect the ideal population in terms of:
❍ Severity of the illness
❍ Duration of the illness
❍ Intra-individual variability
❍ Age
❍ Gender
❍ Further socio-demographic characteristics
❍ Therapy preferences and expectations
❍ Symptoms of the side effects of the interventions
❍ Accompanying illnesses
❍ Accompanying medication
❍ Further prognostic or therapy relevant parameters? (The above listed 
factors can influence the measurement of outcomes so that floor/ceiling-
effects may occur)
• (Is the structural similarity between the study population and the ideal 
population for the intervention tested? – A fairly hypothetical question)
Intervention und control – assessment of performance bias (related 
to MV)
• Is the investigational intervention the optimal treatment?
• In case of medication, is the dosage the optimal treatment?BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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• Is the application the optimal treatment?
• Is the intervention duration the optimal treatment duration? (Are there 
signs of marketing strategies of pharmaceutical companies?)
• Are the permitted accompanying treatments the optimal accompanying 
treatments?
• Are the study conditions the optimal conditions for the intervention?
• Are the interventions carried out by qualified and experienced therapists?
Outcome measurements, results and evaluation – assessment of 
detection and attrition bias (related to MV)
• Do the outcome parameters reflect the effects of the intervention in the 
best possible manner? (Also consider here floor/ceiling effects).
• Do the applied test procedures best reflect the chosen outcomes of 
intervention effects?
• Are the test conditions appropriate to optimally evaluate the intervention 
efficacy?
• Is the length of follow-up sufficient to detect the intervention effects 
(including adverse effects and rebound effects following termination of the 
treatment)?
• Is there an analysis carried out that considers the actually applied treatment 
interventions (PP analysis)?
• Are tests and evaluations carried out by qualified and experienced 
examiners?
• (Retrospectively, were optimal conditions given for the identification of the 
intervention efficacy?)
Study design and setting (related to MV) • Does the research question reflect the optimal conditions for the 
intervention?
• Does the study design ensure a high level of MV?
• Does the study setting reflect the optimal treatment conditions?
• Do the therapists/investigators have adequate experience with the 
intervention or the indication in question?
• Do therapists/investigators and patient have a positive attitude towards the 
intervention?
+ Matches completely/is completely fulfilled
(+) Matches incompletely but sufficiently/is only partly but sufficiently fulfilled
- Does not match or matches insufficiently/is insufficiently fulfilled
c.b.e. Can not be evaluated
Table 3: Questions for assessing model validity (MV) (Continued)BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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Table 4: Information to be collected for ascertaining reference values for external validity (EV) and model validity (MV)
Categories Items
Study population • Characterisation of the routine and optimal indication and population, respectively for the therapy (where appropriate 
with modifications); for what kind of patients with the same or similar conditions are alternative therapies favoured?
• Which diagnostic tests are routinely used in the diagnostic procedure?
• Where possible, typical and optimal patient characterisation in relation to:
❍ Severity of the illness
❍ Duration of illness
❍ Intra-individual variability
❍ Age
❍ Gender
❍ Further socio-demographic characteristics
❍ Therapy preferences and expectations
❍ Symptoms of adverse effects of the interventions
❍ Accompanying illnesses
❍ Accompanying medication
❍ Further prognostic or therapy relevant parameters?
• Therapy expectation for the "everyday" or "optimal" population (are these discussed with the patients)? Data on course 
of illness without treatment?
• Other than the aforementioned characteristics?
• Which patients are not suitable for the intervention and why?
Intervention und Control • Which are the most commonly prescribed or best effective drugs/interventions for the indication/illness in question 
(gold-standard), and how do they differ from the investigational drug/intervention? When will the study intervention be 
selected, when the therapy alternative?
• In case of medication, usual dosage of the therapy; is this related to the optimal effect? (Or is this a reduced dose due to 
adverse effects?)
• Routine method of application of the therapy, is this also the optimal application?
• Routine therapy duration? (Or by continuous application: after which period of time is a treatment-free interval 
considered? When are possible changes to alternative medications considered?)
• Usual accompanying treatments in the therapy of the illness?
• Usual accompanying therapies for commonly associated illnesses? Are interactions with investigational or similar drug/
intervention known?
• Are typical characteristics of the drug/intervention known (e.g. taste, odour, or local irritation following application, 
whereby the intervention can become "un-blinded")?
• Known adverse effects of the intervention?
• Context factors of the usual or optimal interventions treatment (e.g. individual modification of therapy, therapy 
expectation of the physician and patient, kind of medical care, accessibility to the therapy)?
Outcome measurements, results and evaluation • What are the relevant outcomes for the patients (or their relatives) in practice?
• Which parameters are routinely assessed for the progress evaluation of the illness/indication?
• Which outcome measurements best reflect the intervention's efficacy?
• What are the routine assessment procedures for the chosen outcome measurements and their clinically relevant 
threshold values?
• Is intra-individual variability in illness progress accounted for?
• What are the routine conditions for the test procedure?
• What are the optimal conditions for the representation of the intervention efficacy?
• When will the intervention effect become apparent (earliest, latest)?
• When are adverse or rebound effects expected after termination of the application?
• Estimate of the compliance for the intervention (in comparison to alternative therapies), reasons for 
non-compliance or dropouts, for what reasons is the intervention terminated, after what average time 
period?
• (Questions regarding the model validity of individual studies may at best be answered by topic experts)
Study design and setting • What are the clinically relevant research questions?
• Characteristics of best cases/settings and worst cases/settings for the treatment?
• Description of the standard treatment setting (and variability), and optimal setting?
• Are there specifically relevant factors for the indication or therapy?
• Which physicians have the most experience with the intervention or the indication (practice/clinic, 
speciality, level of training, experience)?
• Typical first and subsequent contact with the intervention from the patient's perspective?
• Time and effort for medical care in routine and optimal situations? Other relevant context factors (e.g. 
trust in therapy and/or physician)?
• Time and effort for routine and optimal documentation?
• (For hypothesis testing without comparison group: Is the reference value clinically relevant?)
• Where appropriate: Consult specialists for an evaluation of the closeness to practice of individual 
studies or other factors concerning EV and MV.BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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A study design satisfying the need of IV and EV could be a
4-arm study, in which two arms represent the respective
preference for the test or the control intervention – being
an open and not blinded intervention – while the other
two arms representing the randomised, blinded trial with
genuine equipoise. Further possibilities are studies with
change-to-open-label (COLA) design [24,45] or propen-
sity score analyses; a very high EV is also associated with
the formation and evaluation of medical registers. A par-
ticular ethical problem regarding the equipoise exists in
placebo controlled studies, where patients should in prin-
ciple have the confidence to receive the best therapy and
not solely to be used for the gain of knowledge (see in
addition also Horrobin [46]). Strictly speaking, to warrant
the equipoise only physicians who consider the treat-
ment-free "therapy" or placebo application to be a justi-
fied therapeutic option should carry out placebo-
controlled studies.
An intervention within a study may be altered, e.g. by
individual dose modification or accompanying treat-
ments, satisfying the needs of the everyday life reality. The
intervention itself is seen as needed, but not necessarily as
sufficient in the individual case. Study designs suitable for
these settings are "pragmatic controlled clinical trials"
[21,31,32], which are, however, deficient in IV.
Table 5 Figure 1
Table 5
Table 5  - Using checklist in a parallel form (example)* 
E.g. Data regarding study population – Evaluation of selection bias: 
Extracted 
Information 
Evaluation of 
general study 
quality 
Evaluation of 
Internal Validity (IV) 
Evaluation of 
External Validity (EV) 
Evaluation of Model 
Validity (MV) 
Information to 
be gathered 
from studies, 
therapists, 
investigators, 
affected 
persons or 
participants 
Inclusion 
and
exclusion 
criteria:
 no data 
Are the inclusion 
and exclusion 
criteria clearly and 
sufficiently defined 
to allow replication? 
+ (+) - c.b.e 
Are the inclusion 
and exclusion 
criteria the same for 
the test and control 
groups?
+ (+) - c.b.e 
To what extent do 
the study population 
(defined by the 
inclusion and 
exclusion criteria) 
reflect the general 
or target 
population?
+ (+) - c.b.e 
To what extent do 
the study population 
(defined by the 
inclusion and 
exclusion criteria) 
reflect the optimal 
target population for 
the intervention? 
+ (+) - c.b.e 
Characterisation
of the typical 
and optimal 
indication for 
the intervention. 
* The complete questionnaires including assessment of internal validity and general study 
quality can be obtained by authors. BMC Medical Research Methodology 2006, 6:56 http://www.biomedcentral.com/1471-2288/6/56
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Naturally, the question arises whether the expenditure to
apply the presented checklist is justified. First of all we
want to emphasise that from this checklist's systematised
compilation not all aspects will need to be addressed for
a particular research question and that they also are,
though deliberately, partly redundant. Therefore, the
expenditure in the actual application will be lessened.
When using the checklist in the process of study planning
to decide which aspects should or should not be consid-
ered the already strenuous effort of this process may only
slightly increase. When applying the checklist for the eval-
uation of clinical studies, however, the expenditure is
much more time consuming compared to other, at the
present used, evaluation methods (e.g. Jadad score). How-
ever, it appears to be justified to do so considering the
expenditure in regard to personnel and funding and in
regard to the (psychological) strain for patients to partici-
pate in a study. Studies may otherwise be excluded from a
further evaluation in a meta-analysis or a systematic
review and may not be considered for generating guide-
lines for more or less formal reasons; or they will be
included due to their high IV despite a low EV. Particularly
with respect to the generation of guidelines, which have or
should have a large influence on the decisions about the
therapy, the relevant factors can not be weighted carefully
enough. Furthermore, it could be expected that the accept-
ance of guidelines will be substantially higher in clinical
application, if in the planning of the studies aspects of
external validity were already considered.
Conclusion
IV, EV and MV are important parameters when assessing
clinical studies. Since EV and MV tend to be often
neglected we have created a comprehensive checklist
addressing the different types of validity. The checklist can
be applied to both, planning and evaluating clinical stud-
ies and can be modified according to the actual research
question. It is our hope that this checklist will enhance the
consideration of particularly EV and MV in clinical trials.
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